What should I do if I become drug-resistant after taking Vandetanib?

Vandetanib (Vandetanib) is a potentially effective option for the treatment of advanced medullary thyroid carcinoma (MTC). Additionally, vandetanib appears to be a promising treatment option for patients with advanced dedifferentiated medullary thyroid cancer who are refractory to conventional therapies or RAI. The most important role of vandetanib in aggressive MTC is to prolong PFS and stabilize disease, while overall survival rate remains unchanged.

According to clinical observations, treatment with vandetanib may cause significant side effects(such as fatigue, hypertension, QTc prolongation, rash, mucositis, hand-foot syndrome, nausea, diarrhea, vomiting and thyroid dysfunction), and severe side effects may require suspension of medication. Due to the slow progression, MTC patients may become resistant to the efficacy of vandetanib during long-term treatment due to the activation of alternative mitogenic signals. The effectiveness of treatment could be improved by the possibility of testing the sensitivity of primary TC cells from each subject to different TKIs. It has been shown that combined treatment with bortezomib (a proteasome inhibitor) and EGFR inhibitors (gefitinib, vandetinib, and cetuximab) (in human cancer cell lines expressing EGFR) induces synergistic inhibition of tumor growth. However, since each person's constitution is different and the drug resistance response is also different, please inform your doctor in time if you experience any discomfort.

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.